Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2025)

Haleon (HLN) posted Liabilities and Shareholders Equity of $43.4 billion for Q4 2025, down 1.45% on a QoQ basis from $44.0 billion in Q4 2024, and down 1.45% year-over-year from $44.0 billion in Q4 2024.

Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends

Haleon's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $43.4 billion for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 1.45% year-over-year to $43.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $171.9 billion (changed 0.38% YoY) and the FY2025 annual result came in at $43.0 billion, down 1.92% from the prior year.
  • Liabilities and Shareholders Equity was $43.4 billion for Q4 2025 at Haleon, down from $44.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $56.7 billion in Q2 2022 and bottomed at $40.8 billion in Q4 2022.
  • A 5-year average of $44.8 billion and a median of $43.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slipped 24.57% — and 2024, when it rose 4.2%.
  • Haleon's Liabilities and Shareholders Equity stood at $46.4 billion in 2021, then declined by 12.07% to $40.8 billion in 2022, then increased by 3.51% to $42.3 billion in 2023, then climbed by 4.2% to $44.0 billion in 2024, then slipped by 1.45% to $43.4 billion in 2025.
  • Business Quant data shows HLN's Liabilities and Shareholders Equity at $43.4 billion in Q4 2025, $44.0 billion in Q4 2024, and $42.2 billion in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 928.80 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 43.40 Bn
Dec 31, 2024 44.04 Bn
Jun 30, 2024 42.15 Bn
Dec 31, 2023 42.27 Bn
Jun 30, 2023 42.75 Bn
Dec 31, 2022 40.84 Bn
Jun 30, 2022 56.68 Bn
Dec 31, 2021 46.44 Bn